Alpha 2.0
Login Register
» Articles » PMID: 30222137

JAK2/IDH-mutant-driven Myeloproliferative Neoplasm is Sensitive to Combined Targeted Inhibition

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2018 Sep 18
PMID 30222137
Citations 7
Authors
Anna Sophia McKenney
Allison N Lau
Amritha Varshini Hanasoge Somasundara
Barbara Spitzer
Andrew M Intlekofer
Jihae Ahn
Kaitlyn Shank
Franck T Rapaport
Minal A Patel
Efthymia Papalexi
Alan H Shih
April Chiu
Elizaveta Freinkman
Esra A Akbay
Mya Steadman
Raj Nagaraja
Katharine Yen
Julie Teruya-Feldstein
Kwok-Kin Wong
Raajit Rampal
Matthew G Vander Heiden
Craig B Thompson
Ross L Levine
Affiliations
Soon will be listed here.
Citing Articles

Clonal Architecture in Myeloproliferative Neoplasms: Old Dog, New Tricks?.

Godfrey A Hemasphere. 2023; 7(6):e903.

PMID: 37213328 PMC: 10194568. DOI: 10.1097/HS9.0000000000000903.

Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms.

Luque Paz D, Bader M, Nienhold R, Rai S, Almeida Fonseca T, Stetka J Hemasphere. 2023; 7(5):e885.

PMID: 37153874 PMC: 10158927. DOI: 10.1097/HS9.0000000000000885.

Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective.

Rontauroli S, Carretta C, Parenti S, Bertesi M, Manfredini R Int J Mol Sci. 2022; 23(23).

PMID: 36499582 PMC: 9740017. DOI: 10.3390/ijms232315256.

A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN.

Xiao W, Miles L, Bowman R, Durani V, Tian H, DelGaudio N Blood Adv. 2020; 4(23):6034-6038.

PMID: 33284943 PMC: 7724900. DOI: 10.1182/bloodadvances.2020003326.

Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues.

Hautin M, Mornet C, Chauveau A, Bernard D, Corcos L, Lippert E Cancers (Basel). 2020; 12(8).

PMID: 32784800 PMC: 7464941. DOI: 10.3390/cancers12082216.